213 related articles for article (PubMed ID: 31242951)
21. Comparing deep learning and handcrafted radiomics to predict chemoradiotherapy response for locally advanced cervical cancer using pretreatment MRI.
Jeong S; Yu H; Park SH; Woo D; Lee SJ; Chong GO; Han HS; Kim JC
Sci Rep; 2024 Jan; 14(1):1180. PubMed ID: 38216687
[TBL] [Abstract][Full Text] [Related]
22. Combined pretreatment with
Ji S; Hu Q; Zhu J; Chen J; Chen Q; Liu Z; Shen C; Yang R; Sun H; Wu J; Gu K
Trials; 2018 Aug; 19(1):416. PubMed ID: 30075736
[TBL] [Abstract][Full Text] [Related]
23. Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.
Markovina S; Wang S; Henke LE; Luke CJ; Pak SC; DeWees T; Pfeifer JD; Schwarz JK; Liu W; Chen S; Mutch D; Wang X; Powell MA; Siegel BA; Dehdashti F; Silverman GA; Grigsby PW
Br J Cancer; 2018 Jan; 118(1):72-78. PubMed ID: 29112685
[TBL] [Abstract][Full Text] [Related]
24. Results of concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after previous chemoradiation.
Heijkoop ST; van Doorn HC; Stalpers LJ; Boere IA; van der Velden J; Franckena M; Westermann AM
Int J Hyperthermia; 2014 Feb; 30(1):6-10. PubMed ID: 24156619
[TBL] [Abstract][Full Text] [Related]
25. [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
Monnier L; Touboul E; Daraï E; Lefranc JP; Lauratet B; Ballester M; Huguet F
Bull Cancer; 2016 Feb; 103(2):164-72. PubMed ID: 26822905
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.
Bibby BA; Reynolds JV; Maher SG
PLoS One; 2015; 10(7):e0134180. PubMed ID: 26221725
[TBL] [Abstract][Full Text] [Related]
27. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.
Choi CH; Chung JY; Kang JH; Paik ES; Lee YY; Park W; Byeon SJ; Chung EJ; Kim BG; Hewitt SM; Bae DS
Gynecol Oncol; 2020 May; 157(2):437-443. PubMed ID: 32107047
[TBL] [Abstract][Full Text] [Related]
28. The PRICE study: The role of conventional and diffusion-weighted magnetic resonance imaging in assessment of locally advanced cervical cancer patients administered by chemoradiation followed by radical surgery.
Valentini AL; Miccò M; Gui B; Giuliani M; Rodolfino E; Telesca AM; Pasciuto T; Testa A; Gambacorta MA; Zannoni G; Rufini V; Giordano A; Valentini V; Scambia G; Manfredi R
Eur Radiol; 2018 Jun; 28(6):2425-2435. PubMed ID: 29318432
[TBL] [Abstract][Full Text] [Related]
29. Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial.
Nunes de Arruda F; da Costa S; Bonadio R; Dornellas A; Pereira D; de Bock GH; Del Pilar Estevez Diz M
Int J Gynecol Cancer; 2020 Jun; 30(6):749-756. PubMed ID: 32321767
[TBL] [Abstract][Full Text] [Related]
30. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
[TBL] [Abstract][Full Text] [Related]
31. Pre-hysterectomy cone biopsy is able to predict response in locally advanced cervical cancer patients submitted to neo-adjuvant chemoradiation.
Fanfani F; Fagotti A; Gagliardi ML; Ferrandina G; Monterossi G; Gallotta V; Zannoni GF; Scambia G
Eur J Surg Oncol; 2013 Sep; 39(9):1025-9. PubMed ID: 23827381
[TBL] [Abstract][Full Text] [Related]
32. Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures.
Legge F; Margariti PA; Lucidi A; Macchia G; Petrillo M; Iannone V; Carone V; Morganti AG; Scambia G; Ferrandina G
Acta Oncol; 2013 Jan; 52(1):166-73. PubMed ID: 22746313
[TBL] [Abstract][Full Text] [Related]
33. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
[TBL] [Abstract][Full Text] [Related]
34. Predictors of Radiation Field Failure After Definitive Chemoradiation in Patients With Locally Advanced Cervical Cancer.
Bae HS; Kim YJ; Lim MC; Seo SS; Park SY; Kang S; Kim SH; Kim JY
Int J Gynecol Cancer; 2016 May; 26(4):737-42. PubMed ID: 26937749
[TBL] [Abstract][Full Text] [Related]
35. GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy.
Ueki S; Fujishima F; Kumagai T; Ishida H; Okamoto H; Takaya K; Sato C; Taniyma Y; Kamei T; Sasano H
BMC Cancer; 2020 Feb; 20(1):161. PubMed ID: 32106831
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.
Castelnau-Marchand P; Chargari C; Maroun P; Dumas I; Del Campo ER; Cao K; Petit C; Martinetti F; Tafo-Guemnie A; Lefkopoulos D; Morice P; Haie-Meder C; Mazeron R
Gynecol Oncol; 2015 Nov; 139(2):288-94. PubMed ID: 26364808
[TBL] [Abstract][Full Text] [Related]
37. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI Study): a study protocol of a prospective, single-arm, phase II trial.
Chen J; Han Y; Hu Y; Feng X; Meng X; Guo S; Sun C; Chen G; Li K
BMJ Open; 2023 May; 13(5):e067767. PubMed ID: 37253491
[TBL] [Abstract][Full Text] [Related]
39. Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial.
Dueňas-González A; Orlando M; Zhou Y; Quinlivan M; Barraclough H
Gynecol Oncol; 2012 Sep; 126(3):334-40. PubMed ID: 22691757
[TBL] [Abstract][Full Text] [Related]
40. Cervical cancer response to neoadjuvant chemoradiotherapy: MRI assessment compared with surgery.
Gui B; Valentini AL; Miccò M; D'Agostino GR; Tagliaferri L; Zannoni GF; Fanfani F; Manfredi R; Bonomo L
Acta Radiol; 2016 Sep; 57(9):1123-31. PubMed ID: 26622060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
